Just as predicted, they have been trying to pump the stock and then sell more shares. However, I never expected the pricing for this offer was such low at $6.5 per share which reflected the real price of this stock. This company has a long way to go before we see any promising data or milestone.
I sensed something wrong here. It looks like there was a local tolerability issue with this drug since they just emphasized it did not have significantly systemic clinical AEs. The drug had some local irritation problem before.
I have to agree with you. Not sure when they will start oral Phase 3 program for CABP which will take a long time to enroll. In addition, I guess they are struggling ondevelopment of IV formulatiom for step-down therapy. CEO was taking a lot but she has to show something for real. No near term milestone and not enough cash for Phase 3. Insdiers will start dumping the shares soon. I would consider one of top stocks in my shorting list.